Figure S2. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models Émilie Degagné , Paul D. Donohoue , Suparna Roy , Jessica Scherer , Tristan W. Fowler , Ryan T. Davis , Gustavo A. Reyes , George Kwong , Morena Stanaway , Vanina Larroca Vicena , Devin Mutha , Raymond Guo , Leslie Edwards , Benjamin Schilling , McKay Shaw , Stephen C. Smith , Bryan Kohrs , Heinrich J. Kufeldt , Glen Churchward , Finey Ruan , David B. Nyer , Kyle McSweeney , Matthew J. Irby , Christopher K. Fuller , Lynda Banh , Mckenzi S. Toh , Matthew Thompson , Arthur L.G. Owen , Zili An , Scott Gradia , Justin Skoble , Mara Bryan , Elizabeth Garner , Steven B. Kanner crossref（2024）
摘要
In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.
更多 查看译文
AI 理解论文
溯源树
样例
